Listen

Description

In news from “The Pink Sheet”, we report on how health insurers are reacting to recent tools developed evaluate the value of cancer drugs, concerns about how FDA is handling the Generic Drug User Fee Program and an idea at FDA to conduct centralized reviews of novel surrogate endpoints for accelerated approval of drugs.